Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 112

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 112
---
 breaks and
other cellular damage upon direct impact - within a very short distance. Accordingly, we believe that alpha radiation has several significant
potential advantages for use in cancer radiotherapy, including a high relative biological efficiency (potentially enabling it to destroy
tumor cells with administration of lower levels of radiation), imperviousness to factors such as hypoxia, and a very well-defined range
of travel with limited collateral damage. Nonetheless, its use has also been limited precisely due to alpha’s extremely short particle
range in living tissue, as the range of less than 100 μm is insufficient to provide meaningful clinical utility.

The Alpha DaRT technology
employs a series of radioactive sources that are embedded with Radium-224 to enable a controlled, intratumoral release of alpha-emitting
atoms which diffuse and decay throughout the tumor, seeking to kill cancerous cells with localized precision, while penetrating deeper
into the tumor than can otherwise be reached by the limited ranges of the alpha particles themselves. Due to the inherent limited range
of the alpha particles, we believe that the Alpha DaRT technology has the potential to deliver powerful and localized precise killing
impact to the tumor without damage to surrounding healthy tissue. By combining the innate relative biological effectiveness and short
range of alpha particles in a single-use disposable form, we believe that the Alpha DaRT could address tumors that have otherwise demonstrated
poor response to radiation therapy or other standards of care, with the potential to apply to a wide range of tumors and clinical settings.

We have also devoted a significant
amount of time and resources establishing a robust patent portfolio so as to gain a strong scientific and commercial foothold worldwide.
As of December 31, 2024, our patent portfolio included 151 issued patents, and 217 pending patent applications, including six allowed
patent applications, in the United States, Europe, the United Kingdom, Canada, Japan, Australia, China, South Korea, Israel, Russia, Mexico,
India, Hong Kong, Taiwan, Singapore, South Africa and ARIPO, and four PCT applications.

Our Therapeutic Focus

While we believe the Alpha
DaRT has the potential to revolutionize the treatment of nearly all solid tumors, we have identified three initial areas of therapeutic
focus for the development of our Alpha DaRT technology:

  (1)      Localized and Unresectable - Localized tumors of a type where either current treatment options are inadequate or unavailable for the patient, e.g., refractory  

  (2)